AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2022
Jan 19, 2022
34721_dirs_2022-01-18_c145b147-099c-48a3-b13b-2c45a4a70f72.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-01-18
Reporting Person: Lunger John (Chief Patient Supply Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-18 | American Depositary Shares representing Ordinary Shares | S | 4368 | $3.1918 | Disposed | 7336 | Direct |
Footnotes
F1: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of
approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be
exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell
to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax
withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the
Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs
sold at this price in this footnote.
F3: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this
Form 4. Additionally, the Reporting Person holds 44,988 ADSs and RSU-style options and other options covering an aggregate of 6,302,610 ordinary shares of the Issuer.